# Verastem Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/verastem-oncology

- Industry: Pharmaceuticals
- Headquarters: Needham, US
- Website: www.verastem.com
- Total disclosed funding: $56M
- Latest round: Series C (Nov 21, 2011)
- Investors on record: 6

## About

Founded in 2010 and based in Massachusetts, US, Verastem, Inc. doing business as Verastem Oncology operates as a biopharmaceutical company that engages in the development and commercialization of new medicines. The firm operates under the NASDQ stock exchange, under the ticker symbol VSTM.  In January 2025, Oberland Capital Management provided a USD 150 million credit facility along with an equity investment of USD 7.5 million to Verastem Oncology. The firm, as of January 2025, is led by its President and CEO, Dan Paterson.

 Verastem Oncology focuses on developing therapies for RAS pathway-driven cancers, specifically targeting mutations in the KRAS, NRAS, and HRAS genes. Their core product, avutometinib (previously known as VS-6766), serves as a first-in-class RAF/MEK clamp designed to inhibit signaling through the RAS pathway by holding RAF and MEK in inactive complexes, effectively disrupting tumor growth. Verastem also explores combination therapies with other agents targeting parallel pathways, intending to enhance treatment efficacy. The company's products are primarily for oncology markets within North America, Europe, and select Asia-Pacific regions, catering to healthcare providers and patients seeking advanced cancer treatments.

 The company plans to utilize the January 2025 financing to support the its growth and launch its avutometinib plus defactinib.

## Funding rounds

- Series C, Nov 21, 2011, $20M — Advanced Technology Ventures, Cardinal Partners, Bessemer Venture Partners, MPM BioImpact, Longwood Fund
- Series B, Jul 14, 2011, $32M — Advanced Technology Ventures, Cardinal Partners, Astellas Venture Management, Bessemer Venture Partners, MPM BioImpact, Longwood Fund
- Series A, Nov 3, 2010, $4M — Cardinal Partners, Bessemer Venture Partners, MPM BioImpact, Longwood Fund

## Investors

- Cardinal Partners (https://capitalatlas.ai/funds/cardinal-partners) — Series A, Series B, Series C
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series A, Series B, Series C
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B, Series C
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series A, Series B, Series C
- Advanced Technology Ventures (https://capitalatlas.ai/funds/advanced-technology-ventures) — Series B, Series C
- Astellas Venture Management (https://capitalatlas.ai/funds/astellas-venture-management) — Series B